Women's Mental Health
Mood, hormones, libido, sleep, and medication side effects overlap.
A useful evaluation separates what is hormonal, psychiatric, medication-related, relational, sleep-driven, and medically reversible.
Desire disappeared, so she searched PT-141.
I wanted the medication list first.
That is not me being difficult. Bremelanotide, the prescription drug sold as Vyleesi, is not approved as a shortcut around depression, SSRI side effects, relationship threat, vaginal pain, sleep collapse, or perimenopause. The label basically says the quiet part out loud.
Low desire needs a diagnosis.
The Fast Answer
- PT-141 is not the first question when low desire starts after an SSRI, depression relapse, relationship rupture, pain, perimenopause, or sleep collapse.
- Vyleesi is approved for acquired, generalized HSDD in premenopausal women when low desire is not due to a medical or psychiatric condition, relationship problem, medication, or substance.
- It is not indicated for postmenopausal HSDD or sexual performance.
- It is contraindicated in uncontrolled hypertension and known cardiovascular disease.
- The workup should come before libido medication.
What PT-141 Is
PT-141 is the common name people use online for bremelanotide.
Vyleesi is the FDA-approved bremelanotide product. It is a melanocortin receptor agonist, used as an injection before anticipated sexual activity for acquired, generalized HSDD in premenopausal women.
That is a narrow lane.
I like narrow lanes when drugs affect blood pressure, nausea, and desire circuitry.
DailyMed labeling says Vyleesi is not for low desire caused by a co-existing medical or psychiatric condition, relationship problems, or medication or drug effects. It is also not indicated for postmenopausal women or for enhancing sexual performance.
That exclusion list is where I spend most of the visit.
What I Check First
Depression.
Anxiety.
SSRIs and SNRIs.
Bupropion fit or history.
Hormone stage.
Vaginal dryness or pain.
Trauma.
Sleep.
Thyroid.
Ferritin.
Alcohol.
Cannabis.
Relationship safety.
If any of those changed before desire disappeared, PT-141 may be the wrong first move.
The Medication Story Matters
SSRIs can lower libido and delay orgasm. Depression can lower desire before the SSRI ever enters the picture. Anxiety can make sex feel unsafe. Perimenopause can change sleep, mood, arousal, vaginal tissue, and body image. Pain can train avoidance.
So I do not want the patient to ask only, "Can I get PT-141?"
I want the better question.
Why did desire disappear?
Safety Is Not Fine Print
Vyleesi can raise blood pressure transiently and lower heart rate after dosing. The label contraindicates use in uncontrolled hypertension or known cardiovascular disease. Nausea is common in trials, and some patients discontinued because of it. The label also discusses hyperpigmentation risk, pregnancy precautions, and interactions involving slowed gastric emptying and naltrexone exposure.
That is not casual wellness territory.
I do not treat libido medication like a beauty add-on.
When Sexual Medicine Makes Sense
If the patient has acquired, generalized, distressing low desire and the workup does not point to depression, medication effects, pain, relationship threat, substance use, or another medical cause, sexual medicine or OBGYN referral can make sense.
That is not a failure of psychiatry.
That is the right lane.
Psychiatry should not pretend it owns vaginal pain, menopause care, or sexual medicine. It should also stop ignoring the medication and mood causes that sexual medicine depends on us to catch.
What To Bring
Bring the medication list, dose changes, antidepressant history, mood timeline, trauma history if relevant, sleep pattern, vaginal pain or dryness, hormone history, blood pressure history, cardiovascular history, alcohol, cannabis, and whether desire is low in all situations or only with one partner or context.
Bring the part you think is embarrassing.
That is usually the part that changes the plan.
The Point
PT-141 may have a role for the right patient.
But if low desire is actually depression, SSRI side effect, pain, unsafe relationship dynamics, sleep loss, or perimenopause distress, the drug is being asked to answer the wrong question.
I would rather ask the right one first.
Medical Disclaimer: This article is for education only and is not medical advice. PT-141, Vyleesi, bremelanotide, HSDD, low libido, psychiatric medications, hormones, cardiovascular risk, blood pressure, pregnancy, depression, anxiety, trauma, substances, and sexual pain require individualized evaluation. Do not start, stop, taper, combine, or change psychiatric medications, hormones, supplements, libido treatments, compounded peptides, or prescriptions without guidance from qualified clinicians. Seek urgent help for suicidal thoughts, self-harm urges, mania, psychosis, severe agitation, chest pain, fainting, severe shortness of breath, neurologic symptoms, unsafe blood pressure symptoms, or another emergency. In a mental health crisis, call or text 988.
References
- DailyMed. Vyleesi bremelanotide injection prescribing information. Updated 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
- Kingsberg SA, et al. Bremelanotide phase 3 trials. PMID: 31599840.
- Kingsberg SA, et al. Long-term safety and efficacy of bremelanotide. PMID: 31599847.
- Bremelanotide review. PMID: 35076581.
- HSDD assessment and treatment review. PMID: 34510696.
Written by
Canybec Sulayman APRN, PMHNP-BC, CCRN-CSC
Investigating the root causes of mental health symptoms with 19 years of ICU diagnostic rigor.
Want a plan that fits the whole picture?
Bring the symptoms, medication history, labs, sleep pattern, and questions. The goal is a clearer explanation and safer next step.
